SCHEMBL19706509

SCHEMBL19706509

ONc1nccc2[nH]cnc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.45
MMP12 P39900 1/20 0.41
LMNA P02545 2/20 0.39
PARP1 P09874 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
ALDH1A1 P00352 2/20 0.35
PKM P14618 1/20 0.35
KDM4E B2RXH2 1/20 0.35
EGFR P00533 3/20 0.33
HDAC6 Q9UBN7 1/20 0.33
DRD1 P21728 1/20 0.33
PRNP P04156 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3133619 0.81 EGLN1 (0.42) EGLN1MMP12LMNAPARP1MEN1
SCHEMBL17776527 0.78 EGLN1 (0.50) EGLN1MMP12PARP1MEN1KMT2A
SCHEMBL17778680 0.74 EGLN1 (0.47) EGLN1MMP12PARP1CCNE1CDK2
SCHEMBL13667384 0.74 EGLN1 (0.44) EGLN1MMP12LMNAPARP1CCNE1
SCHEMBL12304499 0.74 LMNA (0.46) EGLN1MMP12LMNAPARP1MEN1
SCHEMBL11023230 0.73 BRD4 (0.52) EGLN1HDAC6HTT
SCHEMBL13667390 0.71 ATR (0.42) EGLN1PARP1CCNE1CDK2MAPT
SCHEMBL22524211 0.70 LMNA (0.52) LMNAALDH1A1KDM4EEGFRHPGD
SCHEMBL19935671 0.69 MMP12 (0.44) EGLN1MMP12LMNAPARP1MEN1
SCHEMBL130593 0.69 MMP12 (0.44) EGLN1MMP12LMNAPARP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355705-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 EGLN1 531/4885MMP12 3474/4885LMNA 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.